Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

A Randomized Controlled Trial Comparing the Efficacy of Topical Vaginal Estrogen Versus Topical Vaginal Estrogen Plus Via, a Hyaluronic Acid-Based Vaginal Moisturizer, in the Treatment of Genitourinary Syndrome of Menopause

This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.

Inclusion Criteria:

• Postmenopausal (last menstrual period at least 12 months ago).
• Aged 45 years or older and have symptoms of Genitourinary Syndrome of Menopause (GSM).
• Have never tried vaginal estrogen therapy, or have tried vaginal estrogen therapy, but have not used vaginal estrogen and/or hyaluronic acid products for management of GSM symptoms within the last 3 months.
• Capable of signing informed consent.
• Capable and willing to follow all study-relation visits.

Exclusion Criteria:

• Subjects currently diagnosed with or undergoing treatment for hormone-sensitive disease (e.g. breast cancer)
• Subjects currently using systemic hormone replacement therapy
• Subjects currently using estrogen hormonal therapies or hormone modulators (aromatase inhibitors or selective estrogen receptor modulators)